Clinical Trial Update: SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of SBRT with Nimotuzumab and Tislelizumab for oligoprogressive recurrent/metastatic nasopharyngeal carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Nasopharyngeal Cancinoma (NPC), SBRT | Phase 2 | Status: RECRUITING